SG11202101817UA - Methods of inhibition - Google Patents

Methods of inhibition

Info

Publication number
SG11202101817UA
SG11202101817UA SG11202101817UA SG11202101817UA SG11202101817UA SG 11202101817U A SG11202101817U A SG 11202101817UA SG 11202101817U A SG11202101817U A SG 11202101817UA SG 11202101817U A SG11202101817U A SG 11202101817UA SG 11202101817U A SG11202101817U A SG 11202101817UA
Authority
SG
Singapore
Prior art keywords
inhibition
methods
Prior art date
Application number
SG11202101817UA
Inventor
Regan Scott Ashby
Original Assignee
Univ Canberra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2018903445A external-priority patent/AU2018903445A0/en
Application filed by Univ Canberra filed Critical Univ Canberra
Publication of SG11202101817UA publication Critical patent/SG11202101817UA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/10Ophthalmic agents for accommodation disorders, e.g. myopia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202101817UA 2018-09-13 2019-09-13 Methods of inhibition SG11202101817UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2018903445A AU2018903445A0 (en) 2018-09-13 Methods of inhibition
PCT/AU2019/050986 WO2020051648A1 (en) 2018-09-13 2019-09-13 Methods of inhibition

Publications (1)

Publication Number Publication Date
SG11202101817UA true SG11202101817UA (en) 2021-03-30

Family

ID=69776469

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202101817UA SG11202101817UA (en) 2018-09-13 2019-09-13 Methods of inhibition

Country Status (10)

Country Link
US (1) US20220047529A1 (en)
EP (1) EP3849533A4 (en)
JP (1) JP7457391B2 (en)
KR (1) KR20210061355A (en)
CN (1) CN112770734A (en)
AU (1) AU2019338938B2 (en)
CA (1) CA3111589C (en)
SG (1) SG11202101817UA (en)
TW (1) TW202023533A (en)
WO (1) WO2020051648A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015095257A2 (en) * 2013-12-18 2015-06-25 Emory University Managing visual dysfunction or loss of vision for diabetic subjects
US20160009705A1 (en) * 2014-06-24 2016-01-14 Sydnexis, Inc. Ophthalmic composition
WO2016187426A1 (en) * 2015-05-19 2016-11-24 Amorphex Therapeutics Llc A device that delivers a sustained low-dose of a myopia-suppressing drug
TW201720443A (en) * 2015-10-09 2017-06-16 梯瓦製藥國際有限責任公司 Combination of deuterated levodopa with carbidopa and opicapone for the treatment of parkinson's disease
CN109310658A (en) * 2016-04-11 2019-02-05 堪培拉大学 Ophthalmic composition comprising levodopa, antioxidant and aqueous carrier
US10155948B2 (en) * 2016-05-12 2018-12-18 Kangwon National University University-Industry Cooperation Foundation and Pharmaceutical composition for preventing or treating diabetic complications and screening method for preventive or therapeutic agent for diabetic complications

Also Published As

Publication number Publication date
CA3111589C (en) 2023-12-19
WO2020051648A1 (en) 2020-03-19
CA3111589A1 (en) 2020-03-19
CN112770734A (en) 2021-05-07
EP3849533A4 (en) 2022-06-22
KR20210061355A (en) 2021-05-27
JP7457391B2 (en) 2024-03-28
EP3849533A1 (en) 2021-07-21
JP2022500405A (en) 2022-01-04
AU2019338938B2 (en) 2023-01-19
US20220047529A1 (en) 2022-02-17
TW202023533A (en) 2020-07-01
AU2019338938A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
IL283639A (en) Kif18a inhibitors
IL281939A (en) Inhibitors of vap-1
EP4069212A4 (en) Inhibitors of hif-2alpha
GB201804514D0 (en) Treatment of pyroptosis
EP3894768C0 (en) Methods of cryo-curing
ZA201904460B (en) Inhibitors of nhe-mediated antiport
GB201806072D0 (en) Methods of manufacture
IL276592A (en) Derivatives of sobetirome
GB201708457D0 (en) Inhibitors of metallo-beta-lactamases
IL281815A (en) Inhibitors of vap-1
IL276013A (en) Pi4kiiibeta inhibitors
GB201804515D0 (en) Treatment of necroptosis
GB201805904D0 (en) Methods of Manufacture
IL281514A (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
GB201708451D0 (en) Inhibitors of metallo-beta-lactamases
IL276107A (en) Solid forms of fasoracetam
IL281409A (en) Musk inhibition
SG11202105136WA (en) Application of chidamide
SG11202101817UA (en) Methods of inhibition
AU2018903445A0 (en) Methods of inhibition
IL283421A (en) Solid state forms of reproxalap
GB201810835D0 (en) Methods of use
AU2018900997A0 (en) Inhibition of ferroptosis
GB201801181D0 (en) Method of use
PT3901141T (en) Novel form of isoquinolinesulfonamide